Chernoguz Artur, Telem Dana A, Chu Edward, Ozao-Choy Junko, Tammaro Yolanda, Divino Celia M
Department of Surgery, Mount Sinai School of Medicine, 5 E. 98th St., New York, NY 10029, USA.
Arch Surg. 2011 Mar;146(3):334-9. doi: 10.1001/archsurg.2011.23.
To determine whether timing of clopidogrel bisulfate cessation influences outcome after abdominal operations.
A review was performed of 104 patients receiving clopidogrel who underwent abdominal operations between March 2003 and March 2009. Patients were grouped by last clopidogrel use: group A (<7 days) and group B (≥7 days).
Of 104 patients, 43 were in group A and 61 were in group B. Overall, 6 deaths occurred (group A, 5 patients [12%] vs group B, 1 [2%]; P = .03) and 27 patients required intensive care unit admission (group A, 16 patients [37%] vs group B, 11 [18%]; P = .03). Twenty-one patients developed a postoperative bleeding complication; 19 complications were managed by blood transfusion and 2 required reoperation. Group A vs group B had significantly increased rates of postoperative bleeding requiring blood transfusion (13 patients [30%] vs 8 [13%]; P = .03). No significant difference in postoperative bleeding resulting in reoperation or mortality was demonstrated. Timing of clopidogrel cessation within 7 days did not affect postoperative bleeding risk. Eighty-nine patients (86%) underwent elective operations (group A, 30 patients [70%] vs group B, 59 [97%]; P < .001). While elective patients in group A vs those in group B demonstrated a trend toward increased risk of postoperative bleeding requiring transfusion (7 patients [23%] vs 8 [14%]; P = .25), no significant difference in intensive care unit admission (group A, 6 patients [20%] vs group B, 9 [15%]; P = .31) or mortality (1 [3%] vs 1 [2%]; P = .62) was demonstrated.
While clopidogrel use within 7 days of an operation significantly increased the risk of postoperative bleeding, most bleeding episodes were successfully managed by transfusion without an increase in bleeding-related mortality or necessity for reoperation. After controlling for operative urgency, no significant difference in mortality or intensive care unit admission was demonstrated in patients undergoing elective procedures. High-risk patients undergoing elective operations may not require preoperative clopidogrel cessation. When clopidogrel cessation is warranted, 7 days before the procedure is recommended. Perioperative risk does not vary by timing of cessation within 7 days of an operation.
确定硫酸氢氯吡格雷停药时间是否会影响腹部手术后的结局。
对2003年3月至2009年3月期间接受氯吡格雷治疗并接受腹部手术的104例患者进行回顾性研究。根据最后一次使用氯吡格雷的时间将患者分组:A组(<7天)和B组(≥7天)。
104例患者中,A组43例,B组61例。总体而言,发生6例死亡(A组5例[12%] vs B组1例[2%];P = 0.03),27例患者需要入住重症监护病房(A组16例[37%] vs B组11例[18%];P = 0.03)。21例患者发生术后出血并发症;19例并发症通过输血处理,2例需要再次手术。A组与B组相比,需要输血的术后出血发生率显著增加(13例[30%] vs 8例[13%];P = 0.03)。在导致再次手术或死亡的术后出血方面未显示出显著差异。在7天内停用氯吡格雷的时间并不影响术后出血风险。89例患者(86%)接受择期手术(A组30例[70%] vs B组59例[97%];P < 0.001)。虽然A组择期手术患者与B组相比,需要输血的术后出血风险有增加趋势(7例[23%] vs 8例[14%];P = 0.25),但在入住重症监护病房(A组6例[20%] vs B组9例[15%];P = 0.31)或死亡率(1例[3%] vs 1例[2%];P = 0.62)方面未显示出显著差异。
虽然在手术7天内使用氯吡格雷会显著增加术后出血风险,但大多数出血事件通过输血成功处理,且未增加出血相关死亡率或再次手术的必要性。在控制手术紧迫性后,接受择期手术的患者在死亡率或入住重症监护病房方面未显示出显著差异。接受择期手术的高危患者可能不需要术前停用氯吡格雷。如果有必要停用氯吡格雷,建议在手术前7天。围手术期风险不会因在手术7天内的停药时间而有所不同。